Ernexa Therapeutics Inc.
ERNANASDAQHealthcareBiotechnology
Regular session
$5.075
+$0.215 · +4.42%
ERNA company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
22
Expensive
Momentum
17
Strong Down
Sentiment
59
Mixed
Risk resilience
21
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteErnexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer. Additionally, Ernexa is developing ERNA-102, an iMSC product engineered to secrete the anti-inflammatory cytokine IL-10, aimed at managing rheumatoid arthritis. The company has a licensing arrangement in place with Factor Bioscience Limited. Established in 2018, this Cambridge, Massachusetts-based entity operated as Eterna Therapeutics Inc. until its rebranding to Ernexa Therapeutics in March 2025.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Sanjeev Luther
- Listed since
- Aug 29, 1991
- Employees
- 5
Market position
Day range
Current $5.075
52-week range
Current $5.075
- Open
- $4.84
- Previous close
- $4.86
- Volume
- 16.39K
- 0.01× average
- Average volume
- 2.09M
- Average daily volume
- Market cap
- 1.62M USD
- Beta
- 2.56
- Market reference 1
- 50-day average
- $5.2684
- -3.67% below average
- 200-day average
- $14.8559
- -65.84% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 6.17M USD
- P/E (TTM)
- -0.27×
- P/B (TTM)
- 1.91×
- P/S (TTM)
- 0×
- EV / EBITDA
- -0.45×
- Earnings yield
- -186.09%
- Free cash flow yield
- -93.20%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -586.59%
- Return on assets
- -241.41%
- Return on invested capital
- -316.61%
Financial health
- Debt / equity
- 0.11×
- Current ratio
- 1.01×
Earnings
- EPS beat rate
- 43%
- 3 beats, 4 misses, 0 met estimates
- Average EPS surprise
- -28.78%
- 7 comparable reports
- Latest EPS result
- -3.4
- Estimate -3.3 · Miss by 3.03%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
ERNA news
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | May 4, 2026 | 1:25 | — | — |
Stock split | Jun 12, 2025 | 1:15 | — | — |
Stock split | Oct 17, 2022 | 1:20 | — | — |
Stock split | Mar 26, 2021 | 1:2 | — | — |
Stock split | Jun 17, 2016 | 1:50 | — | — |
Effective May 4, 2026
1:25
Effective Jun 12, 2025
1:15
Effective Oct 17, 2022
1:20
Effective Mar 26, 2021
1:2
Effective Jun 17, 2016
1:50
ETFs holding ERNA
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research ERNAresearch.disclaimer